KORU Medical Systems, Inc. KRMD R2K
Healthcare · Medical Instruments & Supplies · United States
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.
READ MORE ›$4.06
+50.37% 1Y
Market & Price
Market Cap
$186.49M
Current Price
$4.06
High / Low (52W)
$6.52 / $2.70
Beta
0.42
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
50.75
PEG Ratio
-
Book Value
$0.37
Price to Book
11.06
P/S
4.31
EV/EBITDA
-94.34
Dividend Yield
-
Profitability & Returns
ROCE
-14.86%
ROE
-13.70%
ROA
-5.81%
Profit Margin
-5.27%
Op Margin
-7.35%
EPS (Latest Qtr)
$-0.02
EPS (TTM)
$-0.05
Balance Sheet & Liquidity
Debt/Equity
0.20
Quick Ratio
1.70
Current Ratio
2.33
Debt
$3.37M
Total Assets
$28.20M
Current Assets
$19.99M
Working Capital
$11.79M
Ownership
Promoter Holding
7.96%
Chg in Prom Hold
-
FII / Inst Holding
57.10%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$181.09M
Total Revenue (TTM)
$43.26M
EBITDA
$-1.92M
Free Cash Flow
$874.28K
Operating Cash Flow
$714.53K
Shares Outstanding
45.93M
Gross Margin
61.93%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
13.81%
Profit 5Y
23.18%
Revenue (YoY)
22.10%
Earnings (YoY)
-
PROS
- Compounding revenue at 13.8% over 5 years.
- Profit CAGR of 23.2% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 37.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KRMD KORU Medical Systems, Inc. R2K | 4.06 | - | $186.49M | - | -14.86% | -13.70% | 13.81% | 23.18% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Aug 2014 | Nov 2014 | May 2015 | Aug 2015 | Nov 2015 | May 2016 | Jun 2016 | Aug 2016 | Sep 2016 | Nov 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.03M | 4.50M | 4.55M | 4.97M | 5.35M | 6.62M | 6.33M | 7.71M | 6.08M | 5.43M | 5.53M | 6.04M | 6.24M | 6.55M | 7.76M | 7.39M | 6.94M | 7.00M | 8.20M | 8.43M | - | - | 9.64M | 10.19M | 10.40M | 10.90M | 11.76M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.59M | 3.72M | 4.14M | 4.08M | 4.53M |
| Gross Profit | 1.64M | 1.58M | 1.52M | 2.01M | 2.11M | 1.94M | 1.79M | 1.95M | 2.03M | 2.06M | 2.10M | 2.30M | 2.38M | 2.47M | 2.74M | 2.89M | 3.05M | 3.48M | 4.38M | 3.79M | 4.91M | 3.94M | 3.23M | 3.21M | 3.50M | 3.62M | 3.35M | 4.32M | 4.15M | 3.89M | 4.34M | 5.10M | 5.48M | - | - | 6.05M | 6.48M | 6.26M | 6.82M | 7.23M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.29M | 6.79M | 7.13M | 7.36M | 8.10M |
| Operating Income | 319.06K | 134.43K | -78.86K | 506.78K | 290.21K | -369.60K | -461.46K | -118.96K | -227.60K | -112.47K | 206.06K | 190.34K | 392.38K | 501.13K | 617.01K | 482.69K | -115.04K | 35.88K | 824.48K | 582.82K | -1.03M | 358.83K | -2.21M | -1.38M | -1.32M | -3.13M | -3.61M | -1.53M | -3.06M | -3.22M | -1.79M | -1.96M | -1.19M | - | - | -1.25M | -312.65K | -867.68K | -547.10K | -864.92K |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.03M | -103.17K | -663.20K | -367.93K | -667.39K |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.17M | -189.51K | -778.12K | -482.17K | -807.08K |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 17.36K | -150 | 4.68K | 0 |
| Net Income | 202.99K | 92.69K | -64.64K | 335.21K | 167.55K | -233.31K | -320.21K | -82.61K | -153.21K | -104.28K | 126.95K | 148.47K | 265.75K | 403.43K | 475.72K | 386.55K | -85.39K | 78.18K | 651.81K | 449.43K | -1.08M | 249.18K | -1.28M | -1.12M | -1.09M | -2.54M | -2.92M | -1.23M | -2.41M | -2.50M | -1.37M | -1.94M | -988.72K | - | - | -1.17M | -206.87K | -777.97K | -486.86K | -807.08K |
| Diluted EPS | 0.01 | - | - | 0.01 | - | -0.01 | -0.01 | 0.00 | - | - | - | - | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.02 | 0.01 | -0.03 | 0.01 | -0.03 | -0.03 | -0.02 | -0.06 | -0.07 | -0.03 | -0.05 | -0.05 | -0.03 | 0.04 | 0.02 | -0.03 | - | -0.03 | 0.00 | -0.02 | - | -0.02 |
| R&D Expense | 158.42K | 116.89K | 53.66K | 38.71K | 51.56K | 56.67K | 57.40K | 67.69K | 75.20K | 59.14K | 45.91K | 24.84K | 14.85K | 9.85K | 23.96K | 126.92K | 101.96K | 178.24K | 170.26K | 256.02K | 298.20K | 390.42K | 336.84K | 386.88K | 800.02K | 1.15M | 1.30M | 862.15K | 1.56M | 1.60M | 1.29M | 1.48M | 1.13M | 1.53M | - | 1.11M | 1.19M | 933.11K | - | 1.32M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Feb 2011 | Feb 2012 | Feb 2013 | Feb 2014 | Feb 2015 | Feb 2016 | Feb 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 17.35M | 23.16M | 24.18M | - | 27.90M | 28.52M | 33.65M | 41.13M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 12.53M | 11.81M | 12.31M | 15.52M |
| Gross Profit | - | - | - | 5.31M | 6.69M | 7.60M | 7.57M | 8.14M | 10.81M | 14.85M | 14.94M | - | 15.37M | 16.71M | 21.33M | 25.60M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 26.15M | 26.98M | 27.78M | 28.58M |
| Operating Income | 1.19M | 1.29M | 1.06M | 1.01M | 1.15M | 1.18M | -736.25K | 1.24M | 1.16M | 585.68K | -1.25M | - | -10.78M | -10.27M | -6.45M | -2.97M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -10.19M | -9.40M | -5.56M | -2.16M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -10.68M | -9.77M | -6.06M | -2.62M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | -2.01M | 3.97M | 2.89K | 21.89K |
| Net Income | 704.09K | 815.89K | 725.76K | 703.43K | 753.12K | 782.86K | -535.00K | 904.96K | 910.57K | 564.35K | -1.21M | - | -8.66M | -13.74M | -6.07M | -2.64M |
| Diluted EPS | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | -0.01 | 0.02 | 0.02 | 0.01 | -0.03 | - | -0.19 | -0.30 | -0.13 | -0.06 |
| R&D Expense | 35.52K | 90.33K | 147.58K | 218.15K | 468.15K | 207.28K | 237.49K | 50.59K | 241.12K | 740.48K | 1.30M | 2.47M | 4.96M | 5.74M | 5.26M | 4.39M |
Compounded Sales Growth
| 5 Years: | 13.81% |
| 1 Year: | 22.10% |
Compounded Profit Growth
| 5 Years: | 23.18% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +50.37% |
| 6 Months: | -22.67% |
| 3 Months: | -14.88% |
| 1 Month: | +2.27% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Feb 2010 | Feb 2011 | Feb 2012 | Feb 2013 | Feb 2014 | Feb 2015 | Feb 2016 | Feb 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 3.43M | 4.81M | 5.59M | 6.21M | 7.28M | 8.39M | 8.17M | 9.28M | 10.55M | 13.88M | 39.92M | - | 42.33M | 28.46M | 27.22M | 28.20M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 29.80M | 20.26M | 19.13M | 19.99M |
| Cash & Equivalents | 813.38K | 1.32M | 1.76M | 1.93M | 2.23M | 2.56M | 4.20M | 3.31M | 3.97M | 3.74M | 5.87M | 27.32M | - | 17.41M | 11.48M | 9.58M | 8.87M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.40M | 3.48M | 2.80M | 3.68M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.56M | 4.05M | 5.50M | 5.89M |
| Total Liabilities | - | 954.23K | 1.25M | 1.24M | 1.02M | 1.01M | 1.28M | 1.49M | 1.61M | 1.58M | 2.65M | 3.76M | - | 11.01M | 8.11M | 10.40M | 11.15M |
| Current Liabilities | - | 314.05K | 558.85K | 525.36K | 771.90K | 691.66K | 1.11M | 1.39M | 1.59M | 1.58M | 2.41M | 3.67M | - | 6.96M | 4.45M | 7.20M | 8.19M |
| Long Term Debt | - | - | 439.31K | 393.86K | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.93M | 4.45M | 3.99M | 3.50M |
| Total Equity | 1.69M | 2.48M | 3.55M | 4.36M | 5.19M | 6.27M | 7.12M | 6.68M | 7.67M | 8.96M | 11.24M | 36.16M | - | 31.33M | 20.35M | 16.81M | 17.05M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | 48.86M | 49.09M | 49.40M | 49.81M |
Cash Flows (Annual)
Figures in USD.
| Metric | Feb 2011 | Feb 2012 | Feb 2013 | Feb 2014 | Feb 2015 | Feb 2016 | Feb 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.03M | 560.60K | 784.79K | 954.39K | 826.10K | - | - | 899.91K | 1.48M | 320.62K | -743.32K | - | -5.40M | -4.89M | -319.72K | 462.40K |
| Investing Cash Flow | -353.37K | -339.06K | -568.20K | -218.00K | -744.98K | - | - | -219.28K | -1.73M | 1.31M | -1.04M | - | -2.80M | -814.60K | -1.33M | -949.79K |
| Financing Cash Flow | -166.23K | 213.44K | -43.49K | -439.31K | 248.72K | - | - | -19.36K | 14.43K | 501.30K | 23.22M | - | 279.49K | -218.87K | -248.53K | -221.35K |
| Capital Expenditure | -200.52K | -236.24K | -563.57K | -188.69K | -591.41K | -121.78K | -203.12K | - | - | - | - | - | -2.80M | -814.60K | -1.34M | -956.49K |
| Free Cash Flow | 827.94K | 324.37K | 221.22K | 765.70K | 234.69K | - | - | - | - | - | - | - | -8.21M | -5.71M | -1.66M | -494.08K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -7.93M | -5.93M | -1.90M | -708.74K |
| Share Buybacks | - | - | - | - | 24.28K | - | - | - | - | 2.82K | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Feb 2011 | Feb 2012 | Feb 2013 | Feb 2014 | Feb 2015 | Feb 2016 | Feb 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | 62.3% | 64.1% | 61.8% | - | 55.1% | 58.6% | 63.4% | 62.3% |
| Operating Margin % | - | - | - | - | - | - | - | - | 6.7% | 2.5% | -5.2% | - | -38.6% | -36.0% | -19.2% | -7.2% |
| Net Margin % | - | - | - | - | - | - | - | - | 5.2% | 2.4% | -5.0% | - | -31.0% | -48.2% | -18.0% | -6.4% |
| ROE % | 28.4% | 23.0% | 16.7% | 13.5% | 12.0% | 11.0% | -8.0% | 11.8% | 10.2% | 5.0% | -3.4% | - | -27.6% | -67.5% | -36.1% | -15.5% |
| ROCE % | 38.3% | 30.4% | 21.0% | 18.5% | 17.4% | 16.2% | -10.9% | 16.1% | 13.0% | 5.1% | -3.5% | - | -30.5% | -42.8% | -32.2% | -14.9% |
Shareholding Pattern
Insiders
7.96%
Institutions
57.10%
Public Float
62.04%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | First Light Asset Management, LLC | 9.45% | 3.77M | $15.30M |
| 2 | Topline Capital Management, LLC | 8.81% | 3.51M | $14.27M |
| 3 | Blackrock Inc. | 5.95% | 2.37M | $9.63M |
| 4 | Vanguard Capital Management LLC | 4.23% | 1.69M | $6.85M |
| 5 | Geode Capital Management, LLC | 2.64% | 1.05M | $4.27M |
| 6 | Simcoe Capital LLC | 2.03% | 811.25K | $3.29M |
| 7 | Meros Investment Management, Lp | 1.91% | 760.45K | $3.09M |
| 8 | Empire Financial Management Company, LLC | 1.76% | 703.14K | $2.85M |
| 9 | State Street Corporation | 1.63% | 649.23K | $2.64M |
| 10 | Archon Capital Management LLC | 1.61% | 642.92K | $2.61M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KRMD
No recent headlines available.